Abstracts tagged "SLE and pediatric rheumatology"

Abstract Number: 1385 • 2016 ACR/ARHP Annual Meeting
Frequency of the Systemic Lupus Collaborating Clinics- Damage Index Items in Three Registries of Childhood-Onset Systemic Lupus Erythematosus
Michael J. Holland¹, Michael W. Beresford^2,3,4, Nicolino Ruperto⁵, Allen Watts¹, Kasha Wiley¹, Elisabetta Cortis^5,6, Seza Ozen^5,7, Oscar Porras^5,8, Flavio Sztajnbok^5,9, Maria Apaz^5,10 and Hermine I. Brunner¹, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Department of Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, United Kingdom, ³Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁴On Behalf of the UK JSLE Study Group, Liverpool, United Kingdom, ⁵Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genoa, Italy, ⁶Santa Maria della Stella Hospital, Orvieto, Italy, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁸Hospital Nacional de Niños, San Jose, Costa Rica, ⁹Pediatric Rheumatology Division, Adolescent Health Care Unit, Universida de do Estado do Rio de Janeiro., Rio de Janeiro, Brazil, ¹⁰Pediatric Rheumatology, Hospital de Niños de Cordoba, Córdoba, Argentina
Background/Purpose: Childhood-Onset Systemic Lupus Erythematosus (cSLE) is a chronic, multi-system autoimmune disease. In addition to active inflammation, cSLE may result in irreversible damage to affected…
Abstract Number: 1312 • 2014 ACR/ARHP Annual Meeting
Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus
Roberto Ezequiel Borgia¹, Maya Gerstein¹, Deborah M. Levy², Earl D. Silverman¹ and Linda T Hiraki³, ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Macrophage activation syndrome (MAS) is a life-threatening inflammatory complication of pediatric systemic lupus erythematosus (pSLE). There are few reports of the presentation, treatment and outcome of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].